Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of combining erlotinib and trastuzumab with
paclitaxel in treating patients who have advanced solid tumors. Biological therapies such as
erlotinib may interfere with the growth of the tumor cells and slow the growth of the tumor.
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or
deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining erlotinib and trastuzumab with paclitaxel may kill more tumor cells